Biophysical Assays and Disease - Drug Discovery Digest

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Biophysical Assays

Disease

Site-Specific Molecular Glues for the 14-3-3/Tau pS214 ProteinProtein Interaction via Reversible Covalent Imine Tethering

Covalent Modifiers

FEBRUARY 10, 2025

The interaction of 14-3-3 with Tau, characterized by different phospho-site driven binding modes, forms a valuable, disease-relevant, 14-3-3 multivalent model PPI to explore this selectivity issue.

Biophysical Assays

Biophysical Assays Small Molecule Engineering Regulations

Advancements in hit identification for membrane protein drug discovery

Drug Target Review

APRIL 7, 2025

The challenge of GPCR drug discovery G protein-coupled receptors (GPCRs) are one of the most desirable and challenging target classes in drug discovery, as their mutation can lead to a wide range of diseases such as cancer, cardiovascular disorders and neurological conditions.

Fragment Screening

Fragment Screening Drugs Small Molecule Biophysical Assays

Obstacles and innovations of macrocyclic drug development

Drug Target Review

JANUARY 16, 2025

These sites are commonly involved in protein-protein interactions, some of which are key to disease development. Food and Drug Administration (FDA) approved drugs, macrocycles are used to combat a range of diseases, including cancer, viral, fungal and bacterial infections, neurodegenerative and autoimmune diseases.

Drug Development

Drug Development Small Molecule Drugs FDA Approval

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Site-Specific Molecular Glues for the 14-3-3/Tau pS214 ProteinProtein Interaction via Reversible Covalent Imine Tethering

Advancements in hit identification for membrane protein drug discovery

Obstacles and innovations of macrocyclic drug development

Webinars

Stay Connected